Head and Neck Cancer Market to Witness Growth by (2022-2032), Estimates DelveInsight | Key Companies – Merck KGaA, Adlai Nortye Biopharma, Eli Lilly and Company, Exelixis

The Head and Neck Cancer market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Head and Neck Cancer pipeline products will significantly revolutionize the Head and Neck Cancer market dynamics.

DelveInsight’s “Head and Neck Cancer Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Head and Neck Cancer, historical and forecasted epidemiology as well as the Head and Neck Cancer market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Head and Neck Cancer market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.

To Know in detail about the Head and Neck Cancer market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Head and Neck Cancer Market Insights

Head and Neck Cancer Overview
Head and Neck Cancer (HNC) usually begins in the squamous cells – often referred to as squamous cell carcinomas of the head and neck – that line the mucosal surfaces of the head and neck (for example, those inside the mouth, throat, and voice box. They can also begin in the salivary glands, sinuses, muscles, or nerves, but they are less common than squamous cell carcinomas. HNC begins in several places in the head and throat, excluding brain or eye cancer.

Some of the key facts of the Head and Neck Cancer Market Report:
• The Head and Neck Cancer market size was valued at USD 2801 Million in the year 2021 and is anticipated to grow with a significant CAGR during the study period (2019-2032)
• The total incident cases of Head and Neck Cancer in the 7MM were ~158,000 in 2021, which is expected to increase during the forecast period
• In EU-5, Germany had the highest number of cases with ~20,000 incident cases, followed by France with ~16,000 cases, while Italy had the least number of cases with ~9900 cases in 2021
• Among 7MM, the United States had the highest number of incident cases with ~65,000 cases in 2021, which is nearly 41% of the total cases of Head and Neck Cancer in the7MM
• The analysis from 2021 suggests that the stage-specific incident cases of Head and Neck Cancer (HNC) in the United States were maximum for regional, at ~30,000 cases, followed by localized with ~21,000 cases, distantwith~11,000 cases, and ~3,000 cases of the unknown stage
• Key Head and Neck Cancer Companies: Merck KGaA, Adlai Nortye Biopharma, Eli Lilly and Company, Exelixis, and others
• Key Head and Neck Cancer Therapies: XEVINAPANT (debio 1143), AN2025 (buparlisib), CYRAMZA (ramucirumab), Cabozantinib, and others

Get a Free sample for the Head and Neck Cancer Market Report

Key benefits of the Head and Neck Cancer Market report:

1. Head and Neck Cancer market report covers a descriptive overview and comprehensive insight of the Head and Neck Cancer Epidemiology and Head and Neck Cancer market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2. The Head and Neck Cancer market report provides insights on the current and emerging therapies.
3. Head and Neck Cancer market report provides a global historical and forecasted market covering drug outreach in 7MM.
4. The Head and Neck Cancer market report offers an edge that will help develop business strategies by understanding trends shaping and driving the Head and Neck Cancer market.

Download the report to understand which factors are driving Head and Neck Cancer epidemiology trends @ Head and Neck Cancer Epidemiological Insights

Head and Neck Cancer Market
The dynamics of the Head and Neck Cancer market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecasted period 2019-2032.
“The treatment approach for Head and Neck Cancer patients can involve multiple options like surgery, radiation therapy, chemotherapy, targeted therapy, and immunotherapy. Many cancers of the head and neck are curable, especially if detected at an early stage. Although eliminating the cancer is the primary goal of treatment, preserving the function of the nearby nerves, organs, and tissues is also very important.”

Head and Neck Cancer Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Head and Neck Cancer Epidemiology Segmentation:
The Head and Neck Cancer market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:
• Total Prevalence of Head and Neck Cancer
• Prevalent Cases of Head and Neck Cancer by severity
• Gender-specific Prevalence of Head and Neck Cancer
• Diagnosed Cases of Episodic and Chronic Head and Neck Cancer

Head and Neck Cancer Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Head and Neck Cancer market or expected to get launched during the study period. The analysis covers Head and Neck Cancer market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Head and Neck Cancer Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Discover more about therapies set to grab major Head and Neck Cancer market share @ Head and Neck Cancer market forecast

Head and Neck Cancer Therapies and Key Companies
• XEVINAPANT (debio 1143): Merck KGaA
• AN2025 (buparlisib): Adlai Nortye Biopharma
• CYRAMZA (ramucirumab): Eli Lilly and Company
• Cabozantinib: Exelixis

Head and Neck Cancer Market Strengths
• Survival is steadily improving and it is emphasized that a deeper understanding of tumor pathobiology will lead to improved therapies and outcomes in head and neck cancer
• The understanding of HPV contribution and combinations of various therapies are being investigated in clinical trials. It has been observed that response rates are more when chemotherapy is combined with PD-1 inhibitors in HPV+ tumors. There type of new insights will definitely help in the future

Scope of the Head and Neck Cancer Market Report
• Study Period: 2019–2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Head and Neck Cancer Companies: , and others
• Key Head and Neck Cancer Therapies: XEVINAPANT (debio 1143), AN2025 (buparlisib), CYRAMZA (ramucirumab), Cabozantinib, and others
• Head and Neck Cancer Therapeutic Assessment: Head and Neck Cancer current marketed and Head and Neck Cancer emerging therapies
• Head and Neck Cancer Market Dynamics: Head and Neck Cancer market drivers and Head and Neck Cancer market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
• Head and Neck Cancer Unmet Needs, KOL’s views, Analyst’s views, Head and Neck Cancer Market Access and Reimbursement

Head and Neck Cancer Market Barriers
• An investigation into the use of newer and more active systemic regimens in the neoadjuvant setting to treat Head and Neck Cancer could potentially improve outcomes as there is a lack of randomized neoadjuvant trials. There is no drug approved in the adjuvant and neoadjuvant setting till now, this can be great potential target to the drug makers
• Not many trials are investigating genetic alterations, these mutations may be exploited as potential therapeutic targets providing a unique opportunity for future personalized, targeted therapies.

Table of Contents
1. Head and Neck Cancer Market Report Introduction
2. Executive Summary for Head and Neck Cancer
3. SWOT analysis of Head and Neck Cancer
4. Head and Neck Cancer Patient Share (%) Overview at a Glance
5. Head and Neck Cancer Market Overview at a Glance
6. Head and Neck Cancer Disease Background and Overview
7. Head and Neck Cancer Epidemiology and Patient Population
8. Country-Specific Patient Population of Head and Neck Cancer
9. Head and Neck Cancer Current Treatment and Medical Practices
10. Head and Neck Cancer Unmet Needs
11. Head and Neck Cancer Emerging Therapies
12. Head and Neck Cancer Market Outlook
13. Country-Wise Head and Neck Cancer Market Analysis (2019–2032)
14. Head and Neck Cancer Market Access and Reimbursement of Therapies
15. Head and Neck Cancer Market Drivers
16. Head and Neck Cancer Market Barriers
17. Head and Neck Cancer Appendix
18. Head and Neck Cancer Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

To know more about Head and Neck Cancer treatment, visit @ Head and Neck Cancer Medications

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact

Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting